Prelude Therapeutics Incorporated (PRLD) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
PRLD Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Prelude Therapeutics Incorporated (PRLD) trades at a price-to-earnings ratio of -3.8x, with a stock price of $4.84 and trailing twelve-month earnings per share of $-1.58.
Compared to the Healthcare sector median P/E of 22.1x, PRLD trades at a 117% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, PRLD trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PRLD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PRLD P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 7.8Lowest | -Best | +5167%Best | |
| $7B | 15.2 | -Best | +1747% | |
| $6B | 8.6 | -Best | +264% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See PRLD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRLD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRLD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRLD — Frequently Asked Questions
Quick answers to the most common questions about buying PRLD stock.
Is PRLD stock overvalued or undervalued?
PRLD current P/E: -3.8x. 5-year average P/E: N/A. Percentile: N/A.
How does PRLD's valuation compare to peers?
Prelude Therapeutics Incorporated P/E of -3.8x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is PRLD's PEG ratio?
PRLD PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.